Evommune Presents EVO570 Development Plan Targeting Rheumatoid Arthritis

PUBT · 20h ago
Evommune Presents EVO570 Development Plan Targeting Rheumatoid Arthritis
  • Evommune plans to begin Phase 2 development of EVO570 in rheumatoid arthritis in 2027, targeting data in Q4 2028.
  • Phase 1 is expected to start around late January 2027, with healthy-volunteer data due around mid-2027.
  • Rights outside Greater China involve $20 million upfront cash, $10 million in warrants exercisable for Evommune stock, issued at signing.
  • A $10 million milestone is payable at Phase 2 initiation; royalties range from mid-single to low-double-digit percentages of net sales.
  • Preclinical comparisons showed roughly 20-fold greater VAV1 degradation potency than Novartis’ MRT-6160, with maximum degradation of 99% versus 97%.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evommune Inc. published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.